| Parameters |
Anti-CCP2 |
Anti-MCV |
| r |
p-value |
r p-value |
| Age |
0.264 |
0.231 |
0.359 |
0.65 |
| onset of RA |
0.658 |
0.455 |
0.236 |
0.742 |
| Disease Duration |
0.633 |
0.333 |
0.302 |
0.561 |
| Number of tender joints |
0.222 |
0.432 |
0.301 |
0.543 |
| Number of swollen joints |
0.651 |
0.652 |
-0.053 |
0.344 |
| VAS |
0.561 |
0.003** |
0.747 |
0.005** |
| MS |
0.233 |
0.645 |
-0.341 |
0.123 |
| DAS28 |
0.351 |
0.001** |
0.802 |
0.001** |
| HAQ |
0.321 |
0.356 |
-0.29 |
0.06 |
| ESR |
0.452 |
0.442 |
0.029 |
0.367 |
| CRP |
0.568 |
0.031* |
0.084 |
0.021* |
| RF |
0.529 |
0.032* |
0.560 |
0.312 |
| ANA |
0.333 |
0.051* |
0.651 |
0.231 |
| Anti-CCP2 (U/ml) |
- |
- |
0.483 |
0.001** |
Pearson correlation coefficients between Anti CCP2, Anti MCV R, RF in RA
patients.
RF: Rheumatoid Factor; MS: Morning Stiffness; VAS: Visual Analog Scale of
Pain; DAS28: Disease activity for 28 joint indices score; HAQ: Health Assessment
Questionnaire; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein;
BMI: Body Mass Index. Anti-CCP2: Antibodies against Cyclic Citrullinated Peptide;
Anti-MCV: Antibodies against Mutated Citrullinated Vimentin
*Significant **Highly significant |
